Oncolytic viruses infect, replicate in, and lyse tumour cells but spare the normal ones. One of oncolytic viruses is a naturally occurring replication-competent reovirus (RV), which preferentially kills tumour cells with activated Ras signaling pathways. The aim of this study was to survey effects of RV on brain tumour-derived cells in vitro under hypoxic conditions since hypoxia causes resistance to radio- and chemotherapy. This study demonstrates that RV replicates preferentially in tumour cells and that the virus is able to overcome cellular adaptation to hypoxia and infect and kill hypoxic tumour cells. RV can both replicate in hypoxic tumour microenvironment and cause the cytopathic effect, subsequently inducing cell death. We found that a large proportion of cells are killed in hypoxia (1% O₂) by caspase-independent mechanisms. Furthermore, we learned that the cell death induced by RV in hypoxic conditions is not caused by autophagy.
- MeSH
- apoptóza účinky léků MeSH
- autofagie účinky léků MeSH
- faktor 1 indukovatelný hypoxií - podjednotka alfa metabolismus MeSH
- fibroblasty účinky léků patologie virologie MeSH
- hypoxie buňky účinky léků MeSH
- kaspasa 3 metabolismus MeSH
- kyslík farmakologie MeSH
- lidé MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- onkolytická viroterapie * MeSH
- onkolytické viry účinky léků fyziologie MeSH
- Reoviridae účinky léků fyziologie MeSH
- reovirové infekce patologie virologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Metallothioneins (MTs) are low molecular, cysteine-rich proteins that have naturally-occurring Zn(2+) in both clusters. They may serve as a reservoir of metals for synthesis of apoenzymes and zinc-finger transcription regulators. MTs are also involved with several important proteins e.g. p53, NF-kappaB, PKCl, and GTPase Rab3A. New biological roles for these proteins have been identified including those needed in the carcinogenic process. However, their use as a predictive marker remains controversial. Several reports have disclosed MTs expression as a prognostic factor for tumor progression and drug resistance in a variety of malignancies particularly breast, prostatic, ovarial, head and neck, non-small cell lung cancer, melanoma, and soft tissue sarcoma. The role of MTs as a tumor disease marker or as a cause of resistance in cancer treatment is reviewed and discussed. Moreover, we describe some analytical methods that were developed to detect MTs.
- MeSH
- antitumorózní látky farmakologie MeSH
- chemorezistence MeSH
- cytostatické látky farmakologie MeSH
- lidé MeSH
- metalothionein analýza biosyntéza chemie metabolismus MeSH
- nádory farmakoterapie metabolismus patofyziologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- práce podpořená grantem MeSH
- přehledy MeSH
- MeSH
- adukty DNA * MeSH
- antitumorózní látky MeSH
- cytotoxicita imunologická * MeSH
- elipticiny * farmakokinetika MeSH
- HL-60 buňky * MeSH
- inhibitory angiogeneze analýza MeSH
- lidé MeSH
- MFC-7 buňky * MeSH
- NADPH-cytochrom c-reduktasa * MeSH
- neuroblastom MeSH
- rozpřahující látky * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
- Publikační typ
- abstrakt z konference MeSH
